Abstract:Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. In this paper, we describe a series of novel cyclic peptides derived from an mRNA display screen which inhibit the protein–protein interaction between PCSK9 and LDLR. Using a structure-based drug design approach, we were able to modify our original screening lead 2 to optimize the potency and metabolic stability and minimize the molecular weight to provide novel bicyclic next-generation PCSK9 inhibitor peptides such as 78. These next-generation peptides serve as a critical foundation for continued exploration of potential oral, once-a-day PCSK9 therapeutics for the treatment of cardiovascular disease.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01084?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01084</a>.Representative LC traces for key molecules in the paper, sample IC50 curves for LDLR-FRET and Alexa-FRET assay control peptide, and raw concentration versus time profiles for molecules tested in Mouse IV PK 3D PDB files for each of the new crystal structures have also been uploaded; PDB codes for the crystal structures shown in the paper are as follows: compound 30, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIB">6XIB</a>; compound 40, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIC">6XIC</a>; compound 51, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XID">6XID</a>; compound 78, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIE">6XIE</a>; and compound 84, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIF">6XIF</a>; and authors will release the atomic coordinates and experimental data upon article publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_001.pdf">PDF</a>)6xib (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_002.pdb">PDB</a>)6xic (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_003.pdb">PDB</a>)6xid (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_004.pdb">PDB</a>)6xie (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_005.pdb">PDB</a>)6xif (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_006.pdb">PDB</a>)This article has not yet been cited by other publications.

Abstract 1317: A Proprotein Convertase Subtilisin-like/Kexin Type 9 (Pcsk9)-Binding Antibody, That Structurally Mimics the Egf-a Domain of the LDL-receptor, Lowers LDL-cholesterol in a Transgenic Mouse Model and in Rhesus Monkeys

Abstract 1318: A PCSK9 C-terminal Domain Binding Fab Inhibits PCSK9 Internalization and Restores LDL-uptake

Proprotein Convertase Subtilism/kexin Type 9 Inhibitors: a New Strategy of Regulating Cholesterol

Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia

Progress in the Study of PCSK9 Inhibitors in Lipid Metabolism

The Next Generation of Novel Low-Density Lipoprotein Cholesterol-Lowering Agents: Proprotein Convertase Subtilisin/kexin 9 Inhibitors

Selection and characterization of human PCSK9 antibody from phage displayed antibody library

Proprotein Convertase Subtilisin/kexin Type 9 Potentially Influences Cholesterol Uptake in Macrophages and Reverse Cholesterol Transport

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity

Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity–Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor–Binding Enhancement

Efficacy And Safety Of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody In Adults With Familial Hypercholesterolemia

Engineered Extracellular Vesicles As Nanosponges for Lysosomal Degradation of PCSK9

Heterozygous Ldlr-Deficient Hamster As A Model To Evaluate The Efficacy Of Pcsk9 Antibody In Hyperlipidemia And Atherosclerosis

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design

The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms

Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events